Argos Therapeutics (ARGS) 10-Q 20 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 17, 2018
Document Information [Line Items]
Entity Registrant Name	ARGOS THERAPEUTICS INC
Entity Central Index Key	1,105,533
Trading Symbol	args
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,586,661
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 12,125,661	$ 15,188,838
Assets held for sale		600,000
Prepaid expenses	1,960,954	1,252,134
Other receivables	79,341	143,449
Total current assets	14,165,956	17,184,421
Property and equipment, net	2,611,148	3,582,323
Other assets	11,020	11,020
Total assets	16,788,124	20,777,764
Current liabilities
Accounts payable	113,622	970,650
Accrued expenses	2,569,000	1,263,867
Notes payable	4,979,885	4,972,649
Current portion of other convertible notes	1,835,000	2,350,000
Total current liabilities	9,497,507	9,557,166
Convertible note payable to related party	6,587,098	6,302,959
Long-term portion of other convertible notes	5,540,585	5,830,583
Deferred liabilities	3,298,500	8,153,500
Warrants		167,636
Commitments
Stockholders’ deficit
Preferred stock $0.001 par value; 5,000,000 shares authorized as of December 31, 2017 and June 30, 2018; 0 shares issued and outstanding as of December 31, 2017 and June 30, 2018	0	0
Common stock $0.001 par value; 200,000,000 shares authorized as of December 31, 2017 and June 30, 2018; 5,906,620 and 10,586,661 shares issued and outstanding as of December 31, 2017 and June 30, 2018	10,587	5,907
Accumulated other comprehensive loss	(131,390)	(125,864)
Additional paid-in capital	373,139,547	363,450,204
Accumulated deficit	(381,154,310)	(372,564,327)
Total stockholders’ deficit	(8,135,566)	(9,234,080)
Total liabilities and stockholders’ deficit	$ 16,788,124	$ 20,777,764

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	10,586,661	5,906,620
Common stock, shares outstanding (in shares)	10,586,661	5,906,620

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 54,247	$ 69,693	$ 5,987,180	$ 174,952
Operating expenses
Research and development	3,924,380	5,120,952	9,469,445	13,034,781
General and administrative	2,495,646	2,679,867	4,994,648	6,642,758
Impairment loss on property and equipment				27,204,349
Restructuring costs		344,474		5,352,766
Total operating expenses	6,420,026	8,145,293	14,464,093	52,234,654
Operating loss	(6,365,779)	(8,075,600)	(8,476,913)	(52,059,702)
Other income (expense)
Interest income	19,925	8,881	37,970	39,458
Interest expense	(151,978)	(294,329)	(300,915)	(1,022,760)
Gain on early extinguishment of debt				249,458
Change in fair value of warrant liability	18,534	(177,563)	167,636	20,179,761
Other expense, net	583		(17,762)	(4,905)
Other income (expense), net	(112,936)	(463,011)	(113,071)	19,441,012
Net loss	$ (6,478,715)	$ (8,538,611)	$ (8,589,984)	$ (32,618,690)
Net loss per share, basic and diluted (in dollars per share)	$ (0.61)	$ (4.13)	$ (0.94)	$ (15.78)
Weighted average common shares outstanding, basic and diluted (in shares)	10,584,644	2,068,743	9,109,917	2,067,218

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss	$ (6,478,715)	$ (8,538,611)	$ (8,589,984)	$ (32,618,690)
Other comprehensive gain (loss):
Foreign currency translation gain (loss)	(2,564)	2,628	(5,526)	3,953
Total comprehensive loss	$ (6,481,279)	$ (8,535,983)	$ (8,595,510)	$ (32,614,737)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (6,478,715)	$ (8,538,611)	$ (8,589,984)	$ (32,618,690)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization			943,444	490,701
Compensation expense related to stock options			1,409,490	5,065,654
Issuance of common shares for research and development license agreement			360,000
Gain on early extinguishment of debt				(249,458)
Impairment loss on property and equipment				27,204,349
Decrease in fair value of warrant liability	(18,534)	177,563	(167,636)	(20,179,761)
Loss on disposal of equipment			17,762	13,347
Interest accrued on long-term debt			300,497	453,045
Changes in operating assets and liabilities:
Prepaid expenses and other receivables			(644,712)	(471,760)
Accounts payable			(857,027)	(2,417,702)
Accrued expenses			1,305,132	(1,854,106)
Current portion of restructuring obligation				292,951
Deferred liabilities			(4,855,000)	(55,000)
Manufacturing research and development obligation				181,684
Net cash used in operating activities			(10,778,034)	(24,144,746)
Cash flows from investing activities
Purchase of property and equipment				(3,599,040)
Proceeds from sale of property and equipment			609,884	1,460,615
Net cash (used in) provided by investing activities			609,884	(2,138,425)
Cash flows from financing activities
Net proceeds from sale of common stock			7,924,533	316,152
Proceeds from issuance of convertible note payable				6,000,000
Payments on notes payable			(814,121)	(23,643,786)
Proceeds from exercise of employee stock purchase plan shares				8,369
Net cash (used in) provided by financing activities			7,110,412	(17,357,021)
Effect of exchange rate changes on cash			(5,439)	3,900
Net decrease in cash and cash equivalents			(3,063,177)	(43,636,292)
Beginning of period			15,188,838	52,973,376	$ 52,973,376
End of period	$ 12,125,661	$ 9,337,084	12,125,661	9,337,084	$ 15,188,838
Supplemental disclosure of cash flow information
Cash paid for interest			481	568,240
Supplemental disclosure of noncash investing and financing activities
Issuance of warrants in exchange for early extinguishment of debt				87,100
Purchase of property and equipment included in accounts payable and accrued expenses				2,441,585
Power Generation Agreements [Member]
Cash flows from financing activities
Payments on capital lease obligations				$ (37,756)

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Argos Therapeutics, Inc. (the “Company”), was incorporated in the State of Delaware on May 8, 1997. In the three June 30, 2018, $0.4 three March 31, 2018. not 2018 In April 2018 August 2018, 004, may one no Prior to April 2018, 3 February 2017, 290 290 290 April 2018, four April 2018, 51 February 2017 The Company had also been developing AGS- 004, 1 2 2b 004 004 Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not three six June 30, 2018 not may December 31, 2018 10 10 December 31, 2017. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has evaluated principal conditions and events that may one June 30, 2018, $381.2 June 30, 2018, $14.2 $9.5 $12.1 one three six June 30, 2018 not may On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $23.1 In March 2017, $1.2 December 31, 2017. $3.2 December 31, 2017. In June 2017, $6.0 $6.0 In August 2017, $1.5 $0.85 third 2017 April 2018. In September 2017, $0.5 57,142 $5.2 $8.3 In November 2017, $0.5 34,499 $2.4 December 31, 2019. From June 2017 December 31, 2017, $15.5 December 31, 2017 June 30, 2018, $7.5 April 2018, On April 23, 2018, April 24, 2018 April 25, 2018. As of June 30, 2018, $12.1 not 2018. no In light of the termination of the development of rocapuldencel-T, cessation of the Company’s research and development activities and the Company’s cash resources, and based on a review of the status of its internal programs, resources and capabilities, the Company is exploring a wide range of strategic alternatives that may one no The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia and Argos Therapeutics (Europe) S.à.r.l., the Company’s wholly-owned subsidiary, a société anonyme à responsabilité limitée incorporated in Luxembourg. Significant intercompany transactions and accounts have been eliminated. On January 18, 2018, one twenty Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant Accounting Policies There have been no three six June 30, 2018, 10 December 31, 2017, Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2017 June 30, 2018, $14.7 $11.9 Revenue Recognition An important part of the Company’s business strategy has been to enter into arrangements with third 606, 606” 605, 605” Effective January 1, 2018, 606, January 1, 2018 606, not 605. not January 1, 2018, 606. not January 1, 2018 10 11. no no 605 606 three six June 30, 2018. License Fees and Multiple Element Arrangements. If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are determined to be performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations. If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because it lacks reliable information that would be required to apply an appropriate method of measuring progress, but the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. Development Milestone Payments not not not not Reimbursement of Costs. third 606 10 25 27, Royalty Revenue. not Deferred Revenue. not Summary. three six June 30, 2017, $78,000 $120,000, $27,500 $55,000, three June 30, 2018, $27,000 $27,500 $1.1 six June 30, 2018, $5.8 $57,000 $55,000 $14,000 $11,000 For additional discussion of accounting for collaboration revenues, see Note 11. With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which it recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company’s initial judgments, revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company’s reported financial results. Recently Issued Accounting Pronouncements Not In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. Recently Adopted Accounting Standards In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not 2016 10, Identifying Performance Obligations and Licensing, first 2018.The two 2014 09 no In August 2016, 2016 15, Statement of Cash Flows (Topic 230 not December 15, 2017, January 1, 2018. no In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2018, June 30, 2017: Cash and cash equivalents $ 9,337,084 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 10,077,084 The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows as of December 31, 2016: Cash and cash equivalents $ 52,973,376 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 53,713,376 There was no December 31, 2017 June 30, 2018.

Note 2 - Fair Value of Financia

Note 2 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. The estimated fair values of all of the Company’s financial instruments, excluding long-term debt, approximate their carrying amounts in the consolidated balance sheets as of December 31, 2017 June 30, 2018. As of December 31, 2017 June 30, 2018, December 31, 2017 June 30, 2018, three one three 1, 2, 1, 3, The Company’s Level 1 1 no 2 may The Company’s warrant liability is classified as a Level 3 9 Due to the market value of the Company’s common stock and the $110.00 no June 30, 2018 During the six June 30, 2018 2017, no 1, 2, 3 As of December 31, 2017 June 30, 2018, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Balance as of December 31, 2017 Assets Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 Total assets at fair value $ 4,098,037 $ — $ — $ 4,098,037 Liabilities Warrants $ — $ — $ 167,636 $ 167,636 Total liabilities at fair value $ — $ — $ 167,636 $ 167,636 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Balance as of June 30, 2018 Assets Money-market funds $ 4,126,424 $ — $ — $ 4,126,424 Total assets at fair value $ 4,126,424 $ — $ — $ 4,126,424 Liabilities Warrants $ — $ — $ — $ — Total liabilities at fair value $ — $ — $ — $ — Changes in the fair value of the Company’s Level 3 six June 30, 2018 Balance as of December 31, 2017 $ 167,636 Change in fair value during the period (167,636 ) Balance as of June 30, 2018 $ — The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and estimated fair value of money-market funds included in cash and cash equivalents as of December 31, 2017 June 30, 2018 As of December 31, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 $ 4,098,037 $ — $ — $ 4,098,037 As of June 30, 2018 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,126,424 $ — $ — $ 4,126,424 $ 4,126,424 $ — $ — $ 4,126,424 The fair value of the Company’s debt was derived by evaluating the nature and terms of each note, considering the prevailing economic and market conditions as of each balance sheet date and based on the Level 2 December 31, 2017 $19.1 $19.5 6 June 30, 2018 $18.6 $18.9 6

Note 3 - Restructuring Activiti

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	3. During the six June 30, 2017, December 31, 2017 no six June 30, 2018. six June 30, 2017. As discussed in Note 1, 3 February 2017, 290 three March 31, 2017. $5.4 $27.2 six June 30, 2017 $0.3 three June 30, 2017. Workforce Action Plan On March 10, 2017, 58 48% six June 30, 2017. $1.1 $2.6 six June 30, 2017. CTI Lease Agreement In January 2017, ten two five 40,000 $2.4 March 2017, In March 2017 March 31, 2017, March 17, 2017. $2.4 $0.7 March 2017 $1.7 April 2017 $0.1 no six June 30, 2017, $1.6 $0.9 six June 30, 2017. Impairment of Centerpoint Facility and Construction-in-Progress During the three March 31, 2017, no November 2017, third six June 30, 2017, $18.3

Note 4 - Property and Equipment

Note 4 - Property and Equipment and Assets Held for Sale	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment consist of the following: December 31, 2017 June 30, 2018 Office furniture and equipment $ 639,603 $ 639,603 Computer equipment 989,137 905,323 Computer software 3,146,978 3,143,633 Laboratory equipment 6,050,640 5,914,448 Leasehold improvements 2,435,530 2,435,530 Total property and equipment, gross 13,261,888 13,038,537 Less: Accumulated depreciation and amortization (9,679,565 ) (10,427,389 ) Property and equipment, net $ 3,582,323 $ 2,611,148 The Company sold two December 31, 2018 three March 31, 2018 $0.6 may not

Note 5 - Income Taxes

Note 5 - Income Taxes	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2018. no 2018 no June 30, 2018. Due to the Company’s history of losses since inception, there is not December 31, 2017 June 30, 2018, not not On December 22, 2017, 2017 740 No. 118 not December 31, 2017, may may 2017 2018. three six June 30, 2018, not December 31, 2017.

Note 6 - Notes Payable and Gain

Note 6 - Notes Payable and Gain on Early Extinguishment of Debt	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes payable consist of the following as of December 31, 2017 June 30, 2018: December 31, June 30, Convertible note payable to Pharmstandard, including accrued interest $ 6,302,959 $ 6,587,098 Convertible note payable to Invetech, including accrued interest 5,845,655 5,495,657 Convertible note payable to Saint-Gobain, including accrued interest 2,334,929 1,879,928 Note payable to Medinet, including accrued interest 4,958,824 4,975,181 Other notes payable 13,825 4,704 Total notes payable 19,456,192 18,942,568 Less current portion of convertible note payable to Invetech, including accrued interest (1,300,000 ) (1,050,000 ) Less current portion of convertible note payable to Saint-Gobain, including accrued interest (1,050,000 ) (785,000 ) Less current portion of note payable to Medinet, including accrued interest (4,958,824 ) (4,975,181 ) Less current portion of other notes payable (13,825 ) (4,704 ) Long-term portion of notes payable and convertible notes payable $ 12,133,543 $ 12,127,683 Convertible Note Payable to Invetech. September 22, 2017, $0.5 57,142 $0.2 $5.2 $8.3 $1.5 December 31, 2017. The original principal amount of the Invetech Note is $5.2 September 30, 2020. 6.0% not The Company was required to make quarterly installment payments under the Invetech Note for the fiscal quarters ending December 31, 2017 March 31, 2018, $0.4 $0.2 $0.2 June 30, 2018 March 31, 2019, $0.3 $150,000 $150,000 June 30, 2019 June 30, 2020, $150,000, $0.2 December 31, 2017 three March 31, 2018 $150,000 three June 30, 2018. not December 31, 2017, three March 31, 2018 three June 30, 2018 not The Invetech Note also provides that on the anniversary of the issue date for each of the first three $250,000, no As detailed further below, Invetech may $10.00 • Maturity of the Invetech Note 75 may, not • Change of Control may, not • Default may, not Subject to the aforementioned conversion rights of Invetech, the Company may Convertible Note Payable to Saint-Gobain. November 22, 2017, $0.5 34,499 $2.4 December 31, 2019. The original principal amount of the Saint-Gobain Note is $2.4 September 30, 2020. 6.0% not The Company was required to make quarterly installment payments for the fiscal quarters ending December 31, 2017 March 31, 2018, $340,000, $200,000 $140,000 June 30, 2018 September 30, 2018, $245,000, $125,000 $120,000 December 31, 2018 March 31, 2019, $220,000, $100,000 $120,000 December 31, 2017, March 31, 2018, June 30, 2018, September 30, 2018, December 31, 2018 March 31, 2019, not $4.06 50% June 30, 2019 June 30, 2020, $100,000, $0.3 December 31, 2017 three March 31, 2018 $0.2 three June 30, 2018. not December 31, 2017, three March 31, 2018 three June 30, 2018 not As detailed further below, Saint-Gobain may $10.00 · Maturity of the Note 75 may, not · Change of Control may, not · Default may, not Subject to the aforementioned conversion rights of Saint-Gobain, the Company may Convertible Note Payable to Pharmstandard. On June 15, 2017, $6.0 The Company issued the Pharmstandard Note on June 21, 2017, fifth 9.5% may In addition, at Pharmstandard’s election, Pharmstandard may $10.00. not 39.9% 39.9% may not Pharmstandard is the Company’s largest stockholder, and beneficially owned, in the aggregate, shares representing approximately 14.49% August 17, 2018. two Venture Loan Facility and Gain on Early Extinguishment of Debt. September 2014, $25.0 two $12.5 The Company borrowed the first $12.5 September 2014 second $12.5 August 2015. 9.25% one 0.50% 8.75% one not 10.75%. The Company incurred $0.4 December 31, 2017 The Company made payments with respect to the first $12.5 October 31, 2016, first September 30, 2018. first $0.6 September 30, 2018, $0.6 first second $12.5 18 February 7, 2017, 24 second February 7, 2019. $0.6 February 7, 2019, $0.6 second 3% 24 2% 24 36 1% 36 On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $0.2 December 31, 2017 $1.25 $0.6 Upon the payment of the $23.1 In connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 4,139 $181.20 second September 29, 2021 September 29, 2014, $0.3 December 31, 2017 Medinet Loan. December 2013, 11, $9.0 3.0% December 31, 2018. first not December 31, 2018, December 31, 2018 may $9.0 December 31, 2013, $6.9 8.0%, $2.1 During the year ended December 31, 2015, $1.0 $0.8 $0.2 December 31, 2016, $2.0 $1.5 $0.5 December 31, 2017, $2.0 $1.5 $0.5 Under the agreement, the Company had the right to revoke both the manufacturing license and the sale license to be granted to Medinet or the sale license only. On February 14, 2018, no three March 31, 2018, $5.8 As of December 31, 2017 June 30, 2018, $5.0 $1.9 December 31, 2017 June 30, 2018, $6.9 $1.1 11 Other Notes. November 2013, $77,832 $13,825 $4,704 December 31, 2017 June 30, 2018, 8.31% 60

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. Issuance of Restricted Stock in Six Months Ended June 30, 2017 In lieu of paying certain annual cash bonuses for 2016, January 2017 25% 2016 January 13, 2017. 4,005 $394,534 100% April 17, 2017, In April 2017 368 2,333 $20,999 Issuance of Common Stock in Six Months Ended June 30, 2017 At-the-market Offering In May 2015, $30 415 1933, not May 14, 2015. 3% six June 30, 2017, 41,454 $0.3 Issuance of Restricted Stock in Six Months Ended June 30, 2018 During March 2018, 210,000 April 2018 Issuance of Common Stock in Six Months Ended June 30, 2018 At-the-Market Offering In February 2018, $30 $45 six June 30, 2018, 4,135,993 $7.5 April 2018, Issuance of Common Stock under Collaboration Agreements On April 2, 2018, February 2018, 169,014 11. In January 2018, 375,000 $1.5 March 23, 2018, $450,000. third $1.05 April 2018, $450,000 375,000 $1.05

Note 8 - Stock Incentive Plans

Note 8 - Stock Incentive Plans	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. 2014 2014 In January 2014, 2014 “2014 2014 570,746 first December 31, 2018 December 31, 2024, 250,000 four 4% At the July 28, 2017 2014 2014 300,000 may 2014 first December 31, 2024 134,548 2014 570,746 first December 31, 2018 December 31, 2024, 250,000 four 4% Also in January 2014, 2014 “2014 2014 2014 may 10% 2014 2014 Under the terms of the 2014 85% 85% first first September 2, 2014 February 27, 2015. first 652 85% February 27, 2015 $180.40, $54,508. second March 2, 2015 August 31, 2015. second 1,015 85% August 31, 2015 $124.20, $72,800. third September 1, 2015 February 29, 2016. third 1,814 85% $88.80 February 29, 2016, $107,455. fourth March 1, 2016 August 31, 2016. fourth 1,507 85% fourth $98.20, $63,788. fifth September 1, 2016 February 28, 2017. fifth 428 85% $23.00 February 28, 2017, $30,064. sixth March 1, 2017 August 31, 2017. sixth 999 85% $4.00 August 31, 2017, $17,711. not September 1, 2017. Upon the exercise of stock options, vesting of other awards and purchase of shares through the 2014 2014 2014 2014 June 30, 2018, 309,505 2014 10,899 2014 The Company recorded the following share-based compensation expense: Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Research and development $ 437,598 $ 248,636 $ 925,505 $ 508,429 General and administrative 739,886 445,120 1,488,046 901,061 Restructuring costs 240,499 — 2,652,103 — Total stock-based compensation expense $ 1,417,983 $ 693,756 $ 5,065,654 $ 1,409,490 Allocations to research and development and general and administrative expenses are based upon the department to which the associated employee reported. No 3, $2.7 58 six June 30, 2017. No three June 30, 2017 June 30, 2018. six June 30, 2017, 69,104 $27.00 $101.00 No six June 30, 2018. The following table summarizes the Company’s stock option activity during the six June 30, 2018: Number of Weighted Weighted Outstanding as of December 31, 2017 269,514 $ 111.91 Granted — $ — Exercised — $ — Cancelled (72,165 ) $ 116.49 Outstanding as of June 30, 2018 197,349 $ 118.05 6.72 Exercisable as of June 30, 2018 140,076 $ 119.16 6.16 Vested and expected to vest as of June 30, 2018 192,939 $ 118.11 6.96 Valuation Assumptions for Stock Option Plans and Employee Stock Purchase Plan The employee stock-based compensation expense recognized was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows for the periods indicated: Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Risk-free interest rate 2.27 % — 0.79 % — Dividend yield 0 % — 0 % — Expected option term (in years) 7 — 0.5 — Volatility 86 % — 210 % —

Note 9 - Warrants

Note 9 - Warrants	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Warrants [Text Block]	9. In March 2016, $19.9 182,621 136,966 $107.00. March 14, 2021 June 2016, $29.8 273,933 205,450 $107.00. June 29, 2021 June 2016, 2,803 $0.3 In August 2016, $50.0 454,545 340,909 $110.00 “August 2016 August 2, 2021 As discussed in Note 6 September 2014, second September 29, 2021 March 2017, five 5,000 $26.00 $87,100 December 31, 2017 June 30, 2018. All outstanding warrants were issued with an original life of five December 31, 2017 June 30, 2018, 689,661 Type of Warrant and Classification Date of Issuance Number of Shares Exercise Price Expiration Date(s) Common stock - Equity 9/29/14 4,139 $ 181.20 9/29/21 Common stock - Equity 3/4/16 134,163 $ 107.00 3/4/21 Common stock - Equity 6/29/16 205,450 $ 107.00 6/29/21 Common stock - Liability 8/2/16 340,909 $ 110.00 8/02/21 Common stock - Equity 3/6/17 5,000 $ 26.00 3/06/22 The following warrants were issued in August 2016 December 31, 2017 June 30, 2018, August 2016 August 2016 August 2016 Warrants Exercise price $ 110.00 Expiration date August 2, 2021 Total shares issuable on exercise 340,909 The fair value of the August 2016 five zero August 2016 August 2016 The assumptions used by the Company to determine the fair value of the August 2016 December 31, 2017. $110.00 no June 30, 2018. December 31, 2017 June 30, 2018 Exercise price of warrants $ 110.00 $ 110.00 Closing underlying stock price on date of valuation $ 3.00 $ — Expected stock price volatility 112 % — Expected life (in years) 3.58 — Risk-free interest rate 2.04 % — Expected dividend yield 0.0 % — Valuation per common share underlying each warrant $ 0.49 $ — Total liability for warrants on the consolidated balance sheet $ 167,636 $ — Decrease in fair value during the period 20,758,425 $ 167,636 In 2013, 24,989 $116.40 June 30, 2018, not

Note 10 - Contract with the NIH

Note 10 - Contract with the NIH and NIAID	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. In September 2006, 004. $39.8 $38.4 $1.4 September 2010, September 2010. May 2013. $5.4 May 2013 September 2015. $0.5 September 18, 2014 2 004 June 29, 2016, July 31, 2018. not July 31, 2018. The Company recognized revenue from reimbursements earned in connection with the contract as reimbursable costs were incurred and revenues from the achievement of milestones under the NIH and NIAID contract upon the accomplishment of any such milestone. For the three June 30, 2017 2018, $42,193 $26,747, six June 30, 2017 2018, $119,952 $57,065, $38.1 June 30, 2018 December 31, 2017 June 30, 2018, $31,977 $79,341, no

Note 11 - Collaboration Agreeme

Note 11 - Collaboration Agreements	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Long-term Contracts or Programs Disclosure [Text Block]	11. Pharmstandard License Agreement In August 2013, first may Under the terms of the license agreement, Pharmstandard licensed the Company rights to clinical data generated by Pharmstandard under the agreement and granted the Company an option to obtain an exclusive license outside of the Pharmstandard Territory to develop and commercialize improvements to the Company’s Arcelis technology generated by Pharmstandard under the agreement, a non-exclusive worldwide royalty-free license to Pharmstandard improvements to manufacture products using the Company’s Arcelis technology and a license to specified follow-on licensed products generated by Pharmstandard outside of the Pharmstandard Territory, each on terms to be negotiated upon the Company’s request for a license. In addition, Pharmstandard agreed to pay the Company pass-through royalties on net sales of all licensed products in the low single digits until it has generated a specified amount of aggregate net sales. Once the net sales threshold is achieved, Pharmstandard will pay the Company royalties on net sales of specified licensed products, including rocapuldencel-T, in the low double digits below 20%. twelfth first no third third The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid-up perpetual exclusive licenses. Either party may may third may In November 2013, 24,989 $116.40 not February 2014. Pharmstandard and Actigen Option Agreement On February 1, 2018, PD1 PD1 not one one PD1 $3.6 $8.5 PD1 ten first first $5.0 In consideration for the rights granted under the option agreement, the Company issued 169,014 thirty not sixty Green Cross License Agreement In July 2013, first may Under the terms of the license, Green Cross has agreed to pay the Company $0.5 $0.5 20% fifteenth first The agreement will terminate upon expiration of the royalty term, which is 15 first may may third Medinet License Agreement In December 2013, October 2014. $9.0 In addition, under this agreement, the Company granted Medinet an option to acquire a nonexclusive, royalty-bearing license under the Company’s Arcelis technology to sell in Japan rocapuldencel-T and other products for the treatment of mRCC. The Company refers to the option as the sale option and the license as the sale license. This option expired on April 30, 2016. may may not In consideration for the manufacturing license, Medinet paid the Company $1.0 $9.0 $9.0 $5.0 first first July 2015 $1.0 second June 2016 $2.0 third March 2017 $2.0 December 31, 2017 $4.0 In December 2013, $9.0 3.0% December 31, 2018. not December 31, 2018, December 31, 2018 may The Company recorded the initial $1.0 $9.0 December 31, 2013, $6.9 8.0%, $2.1 December 31, 2015, $1.0 $0.8 $0.2 During the year ended December 31, 2016, $2.0 $1.5 $0.5 December 31, 2016, $6.4 $1.8 $5.4 During the year ended December 31, 2017, $2.0 $1.5 $0.5 December 31, 2017, $5.0 $1.9 $6.9 $6.0 On February 14, 2018, no no $5.8 606 first 2018. June 30, 2018, $5.0 $1.9 $1.1 $150,000 June 30, 2018, $150,000 2018 $150,000 December 31, 2018. The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid up, perpetual non-exclusive licenses. Either party may may third Lummy License Agreement On April 7, 2015, first December 2016, October 2017 March 2018. Under the terms of the License Agreement, the parties will share relevant data, and the Company will have a right to reference Lummy HK data for purposes of its development programs under the Arcelis technology. In addition, Lummy HK has granted to the Company an exclusive, royalty-free license under and to any and all Lummy HK improvements to the Arcelis technology conceived or reduced to practice by Lummy HK (“Lummy HK Improvements”) and Lummy HK data to develop and/or commercialize products (“Arcelis-Based Products”) outside the Territory, an exclusive, royalty-free license under and to any and all investigational new drug applications ("INDs") and other regulatory approvals and Lummy HK trademarks used for an Arcelis-Based Product to develop and/or commercialize an Arcelis-Based Product outside the Territory and a non-exclusive, worldwide, royalty-free license under any Lummy HK Improvements and Lummy HK data to manufacture Arcelis-Based Products anywhere in the world. Lummy HK has the right to reference the Company’s data, INDs and other regulatory filings and submissions for the purpose of developing and obtaining regulatory approval of Licensed Products in the Territory. Pursuant to the License Agreement, Lummy HK will pay the Company royalties on net sales and an aggregate of up to $22.3 10 first may may third Pursuant to the License Agreement, Lummy HK paid the Company a $1.5 October 2017. $1.5 In January 2018, 375,000 $1.5 March 2018, $450,000. third $1.05 April 2018, $450,000 375,000 $1.05 As of June 30, 2018, $2.3 $1.1 third 2018 $1.2 July 1, 2018 December 31, 2029. December 31, 2017 June 30, 2018, $1.2 $2.2

Note 12 - Net Loss Per Share

Note 12 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Basic and diluted net loss per share of common stock was determined by dividing net loss by the weighted average of shares of common stock outstanding during the period. The Company’s potentially dilutive shares, which include options to purchase common stock and warrants, have not The following table presents the computation of basic and diluted net loss per share of common stock: Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Net loss $ (8,538,611 ) $ (6,478,715 ) $ (32,618,690 ) $ (8,589,984 ) Weighted average common shares outstanding, basic and diluted 2,068,743 10,584,644 2,067,218 9,109,917 Net loss per share, basic and diluted $ (4. 13 ) $ (0.61 ) $ (15.78 ) $ (0.94 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding, as they would be antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Stock options outstanding 293,995 200,954 293,452 234,285 Warrants outstanding 689,661 689,661 687,865 689,661 Convertible notes outstanding 1,448,352 1,448,352

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not not three six June 30, 2018 not may December 31, 2018 10 10 December 31, 2017. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has evaluated principal conditions and events that may one June 30, 2018, $381.2 June 30, 2018, $14.2 $9.5 $12.1 one three six June 30, 2018 not may On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $23.1 In March 2017, $1.2 December 31, 2017. $3.2 December 31, 2017. In June 2017, $6.0 $6.0 In August 2017, $1.5 $0.85 third 2017 April 2018. In September 2017, $0.5 57,142 $5.2 $8.3 In November 2017, $0.5 34,499 $2.4 December 31, 2019. From June 2017 December 31, 2017, $15.5 December 31, 2017 June 30, 2018, $7.5 April 2018, On April 23, 2018, April 24, 2018 April 25, 2018. As of June 30, 2018, $12.1 not 2018. no In light of the termination of the development of rocapuldencel-T, cessation of the Company’s research and development activities and the Company’s cash resources, and based on a review of the status of its internal programs, resources and capabilities, the Company is exploring a wide range of strategic alternatives that may one no The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia and Argos Therapeutics (Europe) S.à.r.l., the Company’s wholly-owned subsidiary, a société anonyme à responsabilité limitée incorporated in Luxembourg. Significant intercompany transactions and accounts have been eliminated. On January 18, 2018, one twenty
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant Accounting Policies [Policy Text Block]	Significant Accounting Policies There have been no three six June 30, 2018, 10 December 31, 2017,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2017 June 30, 2018, $14.7 $11.9
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition An important part of the Company’s business strategy has been to enter into arrangements with third 606, 606” 605, 605” Effective January 1, 2018, 606, January 1, 2018 606, not 605. not January 1, 2018, 606. not January 1, 2018 10 11. no no 605 606 three six June 30, 2018. License Fees and Multiple Element Arrangements. If the Company is involved in a steering committee as part of a multiple element arrangement, the Company assesses whether its involvement constitutes a performance obligation or a right to participate. Steering committee services that are determined to be performance obligations are combined with other research services or performance obligations required under an arrangement, if any, in determining the level of effort required in an arrangement and the period over which the Company expects to complete its aggregate performance obligations. If the Company cannot reasonably measure its progress toward complete satisfaction of a performance obligation because it lacks reliable information that would be required to apply an appropriate method of measuring progress, but the Company can reasonably estimate when the performance obligation ceases or the remaining obligations become inconsequential and perfunctory, then revenue is not Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. Development Milestone Payments not not not not Reimbursement of Costs. third 606 10 25 27, Royalty Revenue. not Deferred Revenue. not Summary. three six June 30, 2017, $78,000 $120,000, $27,500 $55,000, three June 30, 2018, $27,000 $27,500 $1.1 six June 30, 2018, $5.8 $57,000 $55,000 $14,000 $11,000 For additional discussion of accounting for collaboration revenues, see Note 11. With respect to each of the foregoing areas of revenue recognition, the Company exercises significant judgment in determining whether an arrangement contains multiple elements, and, if so, how much revenue is allocable to each element. In addition, the Company exercises its judgment in determining when its significant obligations have been met under such agreements and the specific time periods over which it recognized revenue, such as non-refundable, up-front license fees. To the extent that actual facts and circumstances differ from the Company’s initial judgments, revenue recognition with respect to such transactions would change accordingly and any such change could affect the Company’s reported financial results.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Not In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. Recently Adopted Accounting Standards In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not 2016 10, Identifying Performance Obligations and Licensing, first 2018.The two 2014 09 no In August 2016, 2016 15, Statement of Cash Flows (Topic 230 not December 15, 2017, January 1, 2018. no In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2018, June 30, 2017: Cash and cash equivalents $ 9,337,084 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 10,077,084 The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows as of December 31, 2016: Cash and cash equivalents $ 52,973,376 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 53,713,376 There was no December 31, 2017 June 30, 2018.

Note 1 - Organization and Bas20

Note 1 - Organization and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	Cash and cash equivalents $ 9,337,084 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 10,077,084 Cash and cash equivalents $ 52,973,376 Restricted cash included in current assets 740,000 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows $ 53,713,376

Note 2 - Fair Value of Financ21

Note 2 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Balance as of December 31, 2017 Assets Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 Total assets at fair value $ 4,098,037 $ — $ — $ 4,098,037 Liabilities Warrants $ — $ — $ 167,636 $ 167,636 Total liabilities at fair value $ — $ — $ 167,636 $ 167,636 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Balance as of June 30, 2018 Assets Money-market funds $ 4,126,424 $ — $ — $ 4,126,424 Total assets at fair value $ 4,126,424 $ — $ — $ 4,126,424 Liabilities Warrants $ — $ — $ — $ — Total liabilities at fair value $ — $ — $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balance as of December 31, 2017 $ 167,636 Change in fair value during the period (167,636 ) Balance as of June 30, 2018 $ —
Financial Instruments [Table Text Block]	As of December 31, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 $ 4,098,037 $ — $ — $ 4,098,037 As of June 30, 2018 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,126,424 $ — $ — $ 4,126,424 $ 4,126,424 $ — $ — $ 4,126,424

Note 4 - Property and Equipme22

Note 4 - Property and Equipment and Assets Held for Sale (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2017 June 30, 2018 Office furniture and equipment $ 639,603 $ 639,603 Computer equipment 989,137 905,323 Computer software 3,146,978 3,143,633 Laboratory equipment 6,050,640 5,914,448 Leasehold improvements 2,435,530 2,435,530 Total property and equipment, gross 13,261,888 13,038,537 Less: Accumulated depreciation and amortization (9,679,565 ) (10,427,389 ) Property and equipment, net $ 3,582,323 $ 2,611,148

Note 6 - Notes Payable and Ga23

Note 6 - Notes Payable and Gain on Early Extinguishment of Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Debt [Table Text Block]	December 31, June 30, Convertible note payable to Pharmstandard, including accrued interest $ 6,302,959 $ 6,587,098 Convertible note payable to Invetech, including accrued interest 5,845,655 5,495,657 Convertible note payable to Saint-Gobain, including accrued interest 2,334,929 1,879,928 Note payable to Medinet, including accrued interest 4,958,824 4,975,181 Other notes payable 13,825 4,704 Total notes payable 19,456,192 18,942,568 Less current portion of convertible note payable to Invetech, including accrued interest (1,300,000 ) (1,050,000 ) Less current portion of convertible note payable to Saint-Gobain, including accrued interest (1,050,000 ) (785,000 ) Less current portion of note payable to Medinet, including accrued interest (4,958,824 ) (4,975,181 ) Less current portion of other notes payable (13,825 ) (4,704 ) Long-term portion of notes payable and convertible notes payable $ 12,133,543 $ 12,127,683

Note 8 - Stock Incentive Plans

Note 8 - Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Research and development $ 437,598 $ 248,636 $ 925,505 $ 508,429 General and administrative 739,886 445,120 1,488,046 901,061 Restructuring costs 240,499 — 2,652,103 — Total stock-based compensation expense $ 1,417,983 $ 693,756 $ 5,065,654 $ 1,409,490
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted Weighted Outstanding as of December 31, 2017 269,514 $ 111.91 Granted — $ — Exercised — $ — Cancelled (72,165 ) $ 116.49 Outstanding as of June 30, 2018 197,349 $ 118.05 6.72 Exercisable as of June 30, 2018 140,076 $ 119.16 6.16 Vested and expected to vest as of June 30, 2018 192,939 $ 118.11 6.96
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Risk-free interest rate 2.27 % — 0.79 % — Dividend yield 0 % — 0 % — Expected option term (in years) 7 — 0.5 — Volatility 86 % — 210 % —

Note 9 - Warrants (Tables)

Note 9 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Type of Warrant and Classification Date of Issuance Number of Shares Exercise Price Expiration Date(s) Common stock - Equity 9/29/14 4,139 $ 181.20 9/29/21 Common stock - Equity 3/4/16 134,163 $ 107.00 3/4/21 Common stock - Equity 6/29/16 205,450 $ 107.00 6/29/21 Common stock - Liability 8/2/16 340,909 $ 110.00 8/02/21 Common stock - Equity 3/6/17 5,000 $ 26.00 3/06/22
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	December 31, 2017 June 30, 2018 Exercise price of warrants $ 110.00 $ 110.00 Closing underlying stock price on date of valuation $ 3.00 $ — Expected stock price volatility 112 % — Expected life (in years) 3.58 — Risk-free interest rate 2.04 % — Expected dividend yield 0.0 % — Valuation per common share underlying each warrant $ 0.49 $ — Total liability for warrants on the consolidated balance sheet $ 167,636 $ — Decrease in fair value during the period 20,758,425 $ 167,636
August 2016, Warrant [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	August 2016 Warrants Exercise price $ 110.00 Expiration date August 2, 2021 Total shares issuable on exercise 340,909

Note 12 - Net Loss Per Share (T

Note 12 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Net loss $ (8,538,611 ) $ (6,478,715 ) $ (32,618,690 ) $ (8,589,984 ) Weighted average common shares outstanding, basic and diluted 2,068,743 10,584,644 2,067,218 9,109,917 Net loss per share, basic and diluted $ (4. 13 ) $ (0.61 ) $ (15.78 ) $ (0.94 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2018 2017 2018 Stock options outstanding 293,995 200,954 293,452 234,285 Warrants outstanding 689,661 689,661 687,865 689,661 Convertible notes outstanding 1,448,352 1,448,352

Note 1 - Organization and Bas27

Note 1 - Organization and Basis of Presentation (Details Textual)	Jan. 18, 2018	Nov. 22, 2017USD ($)shares	Sep. 22, 2017USD ($)shares	Mar. 06, 2017USD ($)$ / sharesshares	Jun. 30, 2018USD ($)shares	Mar. 16, 2018USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2017USD ($)shares	Aug. 31, 2017USD ($)	Jun. 15, 2017USD ($)	Dec. 31, 2016USD ($)
Research and Development Expense, Total					$ 3,924,380			$ 5,120,952	$ 9,469,445	$ 13,034,781
Retained Earnings (Accumulated Deficit), Ending Balance					(381,154,310)				(381,154,310)		$ (372,564,327)	$ (372,564,327)
Assets, Current, Total					14,165,956				14,165,956		17,184,421	17,184,421
Liabilities, Current, Total					9,497,507				9,497,507		9,557,166	9,557,166
Cash and Cash Equivalents, at Carrying Value, Ending Balance					$ 12,125,661			9,337,084	$ 12,125,661	9,337,084	$ 15,188,838	$ 15,188,838			$ 52,973,376
Extinguishment of Debt, Amount				$ 23,100,000
Class of Warrant or Right, Term				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,000	689,661				689,661		689,661	689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 26
Proceeds from Issuance of Common Stock									$ 7,924,533	316,152
Cash, Uninsured Amount					$ 11,900,000				11,900,000		$ 14,700,000	$ 14,700,000
Revenue from Contract with Customer, Including Assessed Tax					54,247			69,693	5,987,180	174,952
Restricted Cash, Total					0				0		0	0
Grant [Member]
Revenue from Contract with Customer, Including Assessed Tax									11,000
NIH & NIAID [Member]
Revenue from Contract with Customer, Including Assessed Tax					27,000			78,000	57,000	120,000
Lummy Co. Ltd. [Member] | License [Member]
Contract with Customer, Liability, Revenue Recognized					27,500			27,500	55,000	55,000
Revenue from Contract with Customer, Remibursement of Costs									14,000
Lummy Co. Ltd. [Member] | Milestone [Member]
Contract with Customer, Liability, Revenue Recognized					1,100,000
Medinet [Member] | Milestone [Member]
Contract with Customer, Liability, Revenue Recognized									5,800,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Extinguishment of Research and Development Obligation to Invetech [Member]
Extinguishment of Debt, Amount			$ 8,300,000
Repayments of Long-term Debt, Total			$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares			57,142
Extinguishment of Research and Development Obligation to Saint-Gobain [Member]
Repayments of Long-term Debt, Total		$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares		34,499
Medpace, Inc. [Member]
Research and Development Obligation Deferred Fees													$ 1,500,000
Payment of Research and Development Obligation							$ 850,000
Sales Agreement, At-the-market Offering [Member]
Proceeds from Issuance of Common Stock						$ 7,500,000		300,000	$ 7,500,000	6,000,000	$ 15,500,000
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Face Amount								$ 6,000,000		6,000,000				$ 6,000,000
Convertible Note Payable to Invetech Pty Ltd [Member]
Debt Instrument, Face Amount			$ 5,200,000
Repayments of Long-term Debt, Total					$ 150,000							200,000
Convertible Promissory Note to Saint-Gobain [Member]
Debt Instrument, Face Amount		$ 2,400,000
Employee Severance [Member]
Severance Costs										1,100,000		1,200,000
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost										$ 2,600,000		$ 3,200,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 26

Note 1 - Organization and Bas28

Note 1 - Organization and Basis of Presentation - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 12,125,661	$ 15,188,838	$ 9,337,084	$ 52,973,376
Restricted cash included in current assets			740,000	740,000
Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows			$ 10,077,084	$ 53,713,376

Note 2 - Fair Value of Financ29

Note 2 - Fair Value of Financial Instruments (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Mar. 06, 2017	Aug. 02, 2016
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 26
Long-term Debt, Fair Value	$ 18,600,000	$ 19,100,000
Long-term Debt, Total	$ 18,942,568	19,456,192
August 2016, Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 110			$ 110
Warrants and Rights Outstanding	$ 0	$ 167,636

Note 2 - Fair Value of Financ30

Note 2 - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Assets at fair value	$ 4,126,424	$ 4,098,037
Liabilities at fair value		167,636
Warrant Liabilities [Member]
Liabilities at fair value		167,636
Fair Value, Inputs, Level 1 [Member]
Assets at fair value	4,126,424	4,098,037
Liabilities at fair value
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Liabilities at fair value
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Liabilities at fair value		167,636
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities at fair value		167,636
Money Market Funds [Member]
Assets at fair value	4,126,424	4,098,037
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	4,126,424	4,098,037
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value

Note 2 - Fair Value of Financ31

Note 2 - Fair Value of Financial Instruments - Changes in Fair Value for Warrants (Details) - Warrant Liability [Member]	6 Months Ended
	Jun. 30, 2018USD ($)
Balance	$ 167,636
Change in fair value during the period	(167,636)
Balance

Note 2 - Fair Value of Financ32

Note 2 - Fair Value of Financial Instruments - Financial Instruments (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Amortized Cost Basis	$ 4,126,424	$ 4,098,037
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	4,126,424	4,098,037
Money Market Funds [Member]
Amortized Cost Basis	4,126,424	4,098,037
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	$ 4,126,424	$ 4,098,037

Note 3 - Restructuring Activi33

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases (Details Textual)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Mar. 17, 2017USD ($)	Jan. 31, 2017USD ($)ft²
Impairment of Long-Lived Assets Held-for-use					$ 0
Restructuring Charges, Total				$ 344,474		$ 5,352,766
Impairment of Long-Lived Assets to be Disposed of						27,204,349
Restructuring Charges [Member]
Lease Termination Fee						1,600,000
CTI Facility [Member]
Lessee, Operating Lease, Term of Contract									10 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms									2
Area of Real Estate Property | ft²									40,000
Security Deposit								$ 2,400,000	$ 2,400,000
Payments for Unpaid Construction	$ (1,700,000)	$ (700,000)
Lease Arrangement, Refund of Security Deposit	$ 100,000
Lessee, Operating Lease, Renewal Term									5 years
CTI Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of						900,000
Centerpoint Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of						$ 18,300,000
Employee Severance [Member]
Restructuring and Related Cost, Number of Positions Eliminated						58
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent						48.00%
Severance Costs						$ 1,100,000	$ 1,200,000
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost						$ 2,600,000	$ 3,200,000

Note 4 - Property and Equipme34

Note 4 - Property and Equipment and Assets Held for Sale (Details Textual)	3 Months Ended	6 Months Ended
	Mar. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Number of Isolators Sold	2
Proceeds from Sale of Property, Plant, and Equipment, Total		$ 609,884	$ 1,460,615
Isolators [Member]
Proceeds from Sale of Property, Plant, and Equipment, Total	$ 600,000

Note 4 - Property and Equipme35

Note 4 - Property and Equipment and Assets Held for Sale - Property and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 13,038,537	$ 13,261,888
Less: Accumulated depreciation and amortization	(10,427,389)	(9,679,565)
Property and equipment, net	2,611,148	3,582,323
Office Furniture and Equipment [Member]
Property and equipment, gross	639,603	639,603
Computer Equipment [Member]
Property and equipment, gross	905,323	989,137
Computer Software [Member]
Property and equipment, gross	3,143,633	3,146,978
Laboratory Equipment [Member]
Property and equipment, gross	5,914,448	6,050,640
Leasehold Improvements [Member]
Property and equipment, gross	$ 2,435,530	$ 2,435,530

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Income Tax Expense (Benefit), Total	$ 0

Note 6 - Notes Payable and Ga37

Note 6 - Notes Payable and Gain on Early Extinguishment of Debt (Details Textual)	Nov. 22, 2017USD ($)$ / sharesshares	Sep. 22, 2017USD ($)$ / sharesshares	Mar. 06, 2017USD ($)$ / sharesshares	Sep. 29, 2014USD ($)	Aug. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Nov. 30, 2013USD ($)	Mar. 02, 2017	Jun. 30, 2018USD ($)shares	Mar. 31, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Feb. 07, 2019USD ($)	Sep. 30, 2018USD ($)	Aug. 20, 2018	Jun. 21, 2017$ / shares	Jun. 15, 2017USD ($)
Extinguishment of Debt, Amount			$ 23,100,000
Gain (Loss) on Extinguishment of Debt, Total													$ 249,458
Debt Instrument, Periodic Payment, Cash									$ 200,000
Share Price | $ / shares	$ 4.06
Class of Warrant or Right, Term			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			5,000						689,661			689,661		689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 26
Contract with Customer, Liability, Noncurrent									$ 3,298,500			$ 3,298,500		$ 8,153,500
Medinet [Member]
Debt Instrument, Face Amount						$ 9,000,000											$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage						3.00%											3.00%
Proceeds from Notes Payable, Total						$ 9,000,000
Notes Payable, Total						$ 6,900,000			5,000,000			5,000,000		5,000,000	$ 6,400,000		$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage						8.00%											8.00%
Deferred Credits and Other Liabilities, Noncurrent									1,100,000			1,100,000		6,900,000	5,400,000
Reduction in Notes Payable														1,500,000	1,500,000	$ 800,000
Reduction in Deferred Liability														500,000	500,000	200,000
Deferred Revenue, Additions										$ 5,800,000				2,000,000	2,000,000
Debt Instrument, Increase, Accrued Interest												1,900,000		1,900,000	1,800,000
Nonoperating Income (Expense) [Member]
Gain (Loss) on Extinguishment of Debt, Total														200,000
Pharmstandard [Member] | Subsequent Event [Member]
Percentage of Outstanding Common Stock Owned by Related Party																				14.49%
Convertible Note Payable to Invetech Pty Ltd [Member]
Repayments of Long-term Debt, Total									150,000					$ 200,000
Debt Instrument, Face Amount		$ 5,200,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Covenant, Accrued and Unpaid Interest Reduction		$ 250,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 10
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member]
Debt Instrument, Periodic Payment, Cash		$ 200,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Shares Issue, Value		200,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2018 Through March 31, 2019 [Member]
Debt Instrument, Periodic Payment, Cash		150,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2018 Through March 31, 2019 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Total		300,000
Debt Instrument, Periodic Payment, Shares Issue, Value		150,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2019 Through June 30, 2020 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Cash		150,000
Convertible Promissory Note to Saint-Gobain [Member]
Debt Instrument, Face Amount	$ 2,400,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Instrument, Periodic Payment, Cash										300,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member]
Debt Instrument, Periodic Payment, Cash	$ 200,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Total	340,000	400,000
Debt Instrument, Periodic Payment, Shares Issue, Value	140,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2019 Through June 30, 2020 [Member]
Debt Instrument, Periodic Payment, Cash										$ 100,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2018 Through September 30, 2018 [Member]
Debt Instrument, Periodic Payment, Cash	125,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2018 Through September 30, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Total	245,000
Debt Instrument, Periodic Payment, Shares Issue, Value	120,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31, 2018 Through March 31, 2019 [Member]
Debt Instrument, Periodic Payment, Cash	100,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31, 2018 Through March 31, 2019 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Total	220,000
Debt Instrument, Periodic Payment, Shares Issue, Value	120,000
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Face Amount											$ 6,000,000		$ 6,000,000									$ 6,000,000
Debt Instrument, Interest Rate, Stated Percentage																					9.50%
Debt Instrument, Convertible, Conversion Price | $ / shares																					$ 10
Debt Instrument, Convertible, Conversion Prerequisite, Ownership Percentage Can Not Exceed If Converted																					39.90%
Venture Loan and Security Agreement [Member]
Debt Instrument, Face Amount				$ 25,000,000
Debt Instrument, One-Month LIBOR Basis Rate				0.50%
Debt Related Commitment Fees and Debt Issuance Costs				$ 400,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares														4,139
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 181.20
Debt Instrument, Final Payment Waived in Exchange for Issuance of Warrants														$ 1,250,000
Debt Instrument, Prepayment Penalty Waived in Exchange for Issuance of Warrants														600,000
Debt Instrument, Unamortized Discount, Total				$ 300,000
Venture Loan and Security Agreement [Member] | Prepayment on or Before Twenty Four Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance								3.00%
Venture Loan and Security Agreement [Member] | Prepayment After Twenty Four Months But on or Before Thirty Six Months [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance								2.00%
Venture Loan and Security Agreement [Member] | Prepayment After Thirty Six Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance								1.00%
Venture Loan and Security Agreement [Member] | LIBOR Rate In Excess of a Half a Percent [Member]
Debt Instrument, Basis Spread on Variable Rate				9.25%
Venture Loan and Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate				8.75%
Venture Loan and Security Agreement [Member] | Primary Tranche [Member]
Debt Instrument Tranche Amount				$ 12,500,000
Proceeds from Loans				12,500,000	$ 12,500,000
Venture Loan and Security Agreement [Member] | Secondary Tranche [Member]
Debt Instrument Tranche Amount				$ 12,500,000
Venture Loan and Security Agreement [Member] | Secondary Tranche [Member] | Primary Payment Period [Member]
Debt Instrument, Term								1 year 180 days
Venture Loan and Security Agreement [Member] | Secondary Tranche [Member] | Secondary Payment Period [Member]
Debt Instrument, Term								2 years
Venture Loan and Security Agreement [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage				10.75%
Venture Loan and Security Agreement [Member] | Scenario, Forecast [Member] | Primary Tranche [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid																		$ 600,000	$ 600,000
December 2013 Note [Member]
Debt Instrument, Face Amount						$ 9,000,000											$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage						3.00%											3.00%
Proceeds from Notes Payable, Total																	$ 9,000,000
Notes Payable, Total						$ 6,900,000			5,000,000			5,000,000		5,000,000			$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage						8.00%											8.00%
Deferred Credits and Other Liabilities, Noncurrent						$ 2,100,000											$ 2,100,000
Debt Instrument, Increase, Accrued Interest												1,900,000		1,900,000
Contract with Customer, Liability, Noncurrent									$ 1,100,000			$ 1,100,000		6,900,000
December 2013 Note [Member] | Manufacturing License [Member]
Deferred Credits and Other Liabilities, Noncurrent															$ 2,000,000	$ 1,000,000
November 2013 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.31%			8.31%
Proceeds from Notes Payable, Total							$ 77,832
Notes Payable, Total									$ 4,704			$ 4,704		13,825
Debt Instrument, Number of Payments									60			60
Extinguishment of Research and Development Obligation to Invetech [Member]
Repayments of Long-term Debt, Total		$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares		57,142
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 200,000
Extinguishment of Debt, Amount		$ 8,300,000
Gain (Loss) on Extinguishment of Debt, Total														$ 1,500,000
Extinguishment of Research and Development Obligation to Saint-Gobain [Member]
Repayments of Long-term Debt, Total	$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares	34,499

Note 6 - Notes Payable and Ga38

Note 6 - Notes Payable and Gain on Early Extinguishment of Debt - Notes Payable (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Long-term debt	$ 18,942,568	$ 19,456,192
Long-term debt	18,942,568	19,456,192
Long-term portion of notes payable and convertible notes payable	12,127,683	12,133,543
Convertible Note Payable to Pharmstandard [Member]
Long-term debt	6,587,098	6,302,959
Long-term debt	6,587,098	6,302,959
Convertible Note Payable to Invetech Pty Ltd [Member]
Long-term debt	5,495,657	5,845,655
Long-term debt	5,495,657	5,845,655
Less current portion	(1,050,000)	(1,300,000)
Convertible Promissory Note to Saint-Gobain [Member]
Long-term debt	1,879,928	2,334,929
Long-term debt	1,879,928	2,334,929
Less current portion	(785,000)	(1,050,000)
December 2013 Note [Member]
Long-term debt	4,975,181	4,958,824
Long-term debt	4,975,181	4,958,824
Less current portion	(4,975,181)	(4,958,824)
July 2012 Note [Member]
Long-term debt	4,704	13,825
Long-term debt	4,704	13,825
Other Notes Payable [Member]
Less current portion	$ (4,704)	$ (13,825)

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Details Textual) - USD ($)	Apr. 02, 2018	May 08, 2015	Apr. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Jan. 31, 2017	Apr. 02, 2018	Mar. 16, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Mar. 23, 2018	Apr. 17, 2017
Restricted Stock Awards Granted in Lieu of Annual Cash Bonuses, Shares, Percentage of Annual Cash Bonus Used in Calculation							25.00%
Stock Issued During Period, Shares, Restricted Stock Award, Gross							4,005
Stock Issued During Period, Value, Restricted Stock Award, Gross							$ 394,534
Restricted Stock Awards, Lapsing Right of Repurchase, Percentage of Underlying Shares															100.00%
Proceeds from Issuance of Common Stock											$ 7,924,533	$ 316,152
Sales Agreement, At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues										41,454	4,135,993
Proceeds from Issuance of Common Stock									$ 7,500,000	$ 300,000	$ 7,500,000	$ 6,000,000	$ 15,500,000
Stock Purchase Agreement with Lummy HK [Member]
Stock Issued During Period, Shares, New Issues						375,000
Cowen and Company LLC [Member] | Maximum [Member]
Common Stock Sales Agreement, Amount		$ 30,000,000			$ 45,000,000
Common Stock Sales Agreement, Commission of Gross Proceeds		3.00%
Pharmstandard [Member]
Stock Issued During Period, Shares, New Issues	169,014							169,014
Lummy HK [Member]
Stock Issued During Period, Shares, New Issues			375,000
Proceeds from Issuance of Common Stock			$ 450,000
Stock Purchase Agreement, Aggregate Purchase Price						$ 1,500,000								$ 450,000
Proceeds from Milestone Payments			$ 1,050,000
Employee [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross										20,999
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period										368	210,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										2,333	210,000
Restricted Stock [Member] | Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				22

Note 8 - Stock Incentive Plan40

Note 8 - Stock Incentive Plans (Details Textual)	Jul. 28, 2017shares	Feb. 29, 2016USD ($)$ / sharesshares	Jan. 31, 2014shares	Jun. 30, 2018USD ($)shares	Jun. 30, 2017USD ($)shares	Jun. 30, 2018USD ($)shares	Aug. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Feb. 28, 2017USD ($)$ / sharesshares	Aug. 31, 2016USD ($)shares	Aug. 31, 2015USD ($)$ / sharesshares	Feb. 27, 2015USD ($)$ / sharesshares	Nov. 22, 2017$ / shares	Mar. 01, 2016$ / shares
Share Price | $ / shares													$ 4.06
Allocated Share-based Compensation Expense, Total | $				$ 693,756	$ 1,417,983	$ 1,409,490		$ 5,065,654
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0	0	0		69,104
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $ / shares								$ 27
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ / shares								$ 101
Employee Severance [Member]
Allocated Share-based Compensation Expense, Total | $								$ 2,700,000
Restructuring and Related Cost, Number of Positions Eliminated								58
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			570,746
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Future Increases in the Number of Shares Authorized	250,000		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percent of Shares Outstanding			4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Automatic Annual Increase	134,548
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Before Annual Increases	570,746
Share-based Compensation Arrangement by Share-based Payment Award, Future Increases in the Number of Shares Authorized, Percent of Shares Outstanding	4.00%
Common Stock, Capital Shares Reserved for Future Issuance				309,505		309,505
The 2014 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate			10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent			85.00%
Employee Stock Purchase Plan (ESPP), Number of Shares Allocated		1,814					999		428	1,507	1,015	652
Share Price | $ / shares		$ 88.80					$ 4		$ 23		$ 124.20	$ 180.40		$ 98.20
Allocated Share-based Compensation Expense, Total | $		$ 107,455					$ 17,711		$ 30,064	$ 63,788	$ 72,800	$ 54,508
Common Stock, Capital Shares Reserved for Future Issuance				10,899		10,899
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense | $						$ 0

Note 8 - Stock Incentive Plan41

Note 8 - Stock Incentive Plans - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock-based compensation expense	$ 693,756	$ 1,417,983	$ 1,409,490	$ 5,065,654
Research and Development Expense [Member]
Stock-based compensation expense	248,636	437,598	508,429	925,505
General and Administrative Expense [Member]
Stock-based compensation expense	445,120	739,886	901,061	1,488,046
Restructuring Charges [Member]
Stock-based compensation expense		$ 240,499		$ 2,652,103

Note 8 - Stock Incentive Plan42

Note 8 - Stock Incentive Plans - Stock Option Activity (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Number of Shares Outstanding, Beginning Balance (in shares)			269,514
Weighted Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)			$ 111.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0	0	69,104
Weighted Average Exercise Price, Granted (in dollars per share)
Number of Shares Exercised (in shares)
Weighted Average Exercise Price, Exercised (in dollars per share)
Number of Shares Cancelled (in shares)			(72,165)
Weighted Average Exercise Price, Cancelled (in dollars per share)			$ 116.49
Number of Shares Outstanding, Ending Balance (in shares)	197,349		197,349
Weighted Average Exercise Price, Outstanding, Ending Balance (in dollars per share)	$ 118.05		$ 118.05
Weighted Average Contractual Term, Outstanding, Ending Balance (Year)			6 years 262 days
Number of Shares Exercisable (in shares)	140,076		140,076
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 119.16		$ 119.16
Weighted Average Contractual Term, Exercisable (Year)			6 years 58 days
Number of Shares Vested and Expected to Vest (in shares)	192,939		192,939
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)	$ 118.11		$ 118.11
Weighted Average Contractual Term, Vested and Expected to Vest (Year)			6 years 350 days

Note 8 - Stock Incentive Plan43

Note 8 - Stock Incentive Plans - Stock Option Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Stock Option Plans [Member]
Risk-free interest rate		2.27%
Dividend yield		0.00%
Expected option term (Year)		7 years
Volatility		86.00%
Employee Stock Purchase Plan [Member]
Risk-free interest rate		0.79%
Dividend yield		0.00%
Expected option term (Year)		182 days
Volatility		210.00%

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual)	Apr. 02, 2018shares	Mar. 06, 2017$ / sharesshares	Jun. 29, 2016USD ($)$ / sharesshares	Mar. 14, 2016USD ($)$ / sharesshares	Aug. 31, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)shares	Apr. 02, 2018shares	Jun. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Aug. 02, 2016$ / sharesshares	Nov. 30, 2013$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,000						689,661	689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 26
Class of Warrant or Right, Term		5 years
August 2016, Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										340,909
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 110		$ 110
Warrants and Rights Outstanding | $								$ 0	$ 167,636
August 2016, Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0				0
Lenders and Affiliates [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 26
Class of Warrant or Right, Term		5 years						5 years
Lenders and Affiliates [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding | $								$ 87,100	$ 87,100
Pharmstandard [Member]
Stock Issued During Period, Shares, New Issues	169,014						169,014
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											24,989
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 116.40
Private Placement [Member] | Investors [Member]
Stock Issued During Period, Value, New Issues | $			$ 29,800,000	$ 19,900,000
Stock Issued During Period, Shares, New Issues			273,933	182,621
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			205,450	136,966
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 107	$ 107
Class of Warrant or Right, Exercised During Period						2,803
Proceeds from Warrant Exercises | $						$ 300,000
Underwritten Offering [Member]
Stock Issued During Period, Shares, New Issues					454,545
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					340,909
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 110
Total Purchase Price of Shares and Warrants Sold | $					$ 50,000,000

Note 9 - Warrants - Outstanding

Note 9 - Warrants - Outstanding Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Mar. 06, 2017
Number of shares (in shares)	689,661	689,661	5,000
Exercise price (in dollars per share)			$ 26
Warrant One [Member]
Number of shares (in shares)	4,139
Exercise price (in dollars per share)	$ 181.20
Expiration date	Sep. 29, 2021
Warrant Two [Member]
Number of shares (in shares)	134,163
Exercise price (in dollars per share)	$ 107
Expiration date	Mar. 4, 2021
Warrant Three [Member]
Number of shares (in shares)	205,450
Exercise price (in dollars per share)	$ 107
Expiration date	Jun. 29, 2021
Warrant Four [Member]
Number of shares (in shares)	340,909
Exercise price (in dollars per share)	$ 110
Expiration date	Aug. 2, 2021
Warrant Five [Member]
Number of shares (in shares)	5,000
Exercise price (in dollars per share)	$ 26
Expiration date	Mar. 6, 2022

Note 9 - Warrants - August 2016

Note 9 - Warrants - August 2016, Warrants (Details) - $ / shares	Aug. 02, 2016	Jun. 30, 2018	Dec. 31, 2017	Mar. 06, 2017
Exercise price (in dollars per share)				$ 26
Number of Shares Called by Warrants (in shares)		689,661	689,661	5,000
August 2016, Warrant [Member]
Exercise price (in dollars per share)	$ 110	$ 110
Expiration date	Aug. 2, 2021
Number of Shares Called by Warrants (in shares)	340,909

Note 9 - Warrants - Warrants Va

Note 9 - Warrants - Warrants Valuation Assumptions (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018USD ($)yr$ / shares	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)yr$ / shares	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)yr$ / shares	Nov. 22, 2017$ / shares	Aug. 31, 2016
Closing underlying stock price on date of valuation (in dollars per share) | $ / shares						$ 4.06
Decrease in fair value of warrant liability | $	$ (18,534)	$ 177,563	$ (167,636)	$ (20,179,761)
August 2016, Warrant [Member]
Closing underlying stock price on date of valuation (in dollars per share) | $ / shares					$ 3
Valuation per common share underlying each warrant (in dollars per share) | $ / shares					$ 0.49
Total liability for warrants on the consolidated balance sheet | $	$ 0		$ 0		$ 167,636
Decrease in fair value of warrant liability | $			$ 167,636		$ 20,758,425
August 2016, Warrant [Member] | Measurement Input, Exercise Price [Member]
Warrants and rights outstanding, measurement input	110		110		110
August 2016, Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and rights outstanding, measurement input					1.12
August 2016, Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and rights outstanding, measurement input | yr					3.58
August 2016, Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and rights outstanding, measurement input					0.0204
August 2016, Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and rights outstanding, measurement input					0		0

Note 10 - Contract with the N48

Note 10 - Contract with the NIH and NIAID (Details Textual) - NIH & NIAID [Member] - USD ($)	Sep. 18, 2014	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Sep. 30, 2015	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2006
Unattained Funds, Contracted Commitment									$ 39,800,000
Increase in Unattained Funds, Contracted Commitment	$ 500,000					$ 5,400,000
Revenues, Total		$ 26,747	$ 42,193	$ 57,065	$ 119,952		$ 38,100,000
Accounts Receivable, Net, Current, Total		$ 79,341		$ 79,341			$ 79,341	$ 31,977
Operating Expense [Member]
Unattained Funds, Contracted Commitment									38,400,000
Other Specified [Member]
Unattained Funds, Contracted Commitment									$ 1,400,000

Note 11 - Collaboration Agree49

Note 11 - Collaboration Agreements 1 (Details Textual) - USD ($)	Apr. 02, 2018	Feb. 01, 2018	Jul. 31, 2013	Apr. 30, 2018	Oct. 31, 2017	Jun. 30, 2016	Jul. 31, 2015	Dec. 31, 2013	Apr. 02, 2018	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 23, 2018	Jan. 31, 2018	Mar. 06, 2017	Nov. 30, 2013	Aug. 31, 2013
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											689,661		689,661					5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																		$ 26
Proceeds from Issuance of Common Stock											$ 7,924,533	$ 316,152
Pharmstandard and Actigen Option Agreement [Member]
Collaborative Arrangement, Upfront License Fee		$ 3,600,000
Collaborative Arrangement, Development and Regulatory Milestone Payments		$ 8,500,000
Collaborative Arrangement, Royalty Payment, Minimum Term		10 years
Collaborative Arrangement, Development Expenditures Credited as Prepaid Royalties		$ 5,000,000
Medinet [Member]
Debt Instrument, Face Amount								$ 9,000,000
Lummy License Agreement [Member]
Contract with Customer, Liability, Total											2.20		$ 1,200,000
Revenue Recognition Milestone Method, Maximum Revenue											$ 22,300,000
License Agreement Royalty Term											10 years
Proceeds from Milestone Payments					$ 1,500,000
Revenue Recognition, Milestone Method, Revenue Recognized					$ 1,500,000
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			24,989
Class of Warrant or Right, Exercise Price of Warrants or Rights																			$ 116.40
Stock Issued During Period, Shares, New Issues	169,014								169,014
Green Cross [Member]
Royalty Contract Term			15 years
Green Cross [Member] | Initial Submission of Application for Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount			$ 500,000
Medinet [Member]
Royalty Guarantees, Commitments, Amount								5,000,000
Debt Instrument, Face Amount								9,000,000
Proceeds from License Fees Received						$ 2,000,000	$ 1,000,000	1,000,000					2,000,000
Proceeds from Notes Payable, Total								$ 9,000,000
Debt Instrument, Principal Balance													4,000,000
Debt Instrument, Interest Rate, Stated Percentage								3.00%
Deferred Credits and Other Liabilities, Noncurrent											$ 1,100,000		6,900,000	$ 5,400,000
Notes Payable, Total								$ 6,900,000			5,000,000		5,000,000	6,400,000
Debt Instrument, Interest Rate, Effective Percentage								8.00%
Deferred Revenue															$ 1,000,000
Reduction in Notes Payable													1,500,000	1,500,000	800,000
Reduction in Deferred Liability													500,000	500,000	$ 200,000
Deferred Revenue, Additions										$ 5,800,000			2,000,000	2,000,000
Debt Instrument, Increase, Accrued Interest											1,900,000		1,900,000	$ 1,800,000
Contract with Customer, Liability, Total											150,000		$ 6,000,000
Contract with Customer, Liability, Revenue Recognized											5,800,000
Revenue, Remaining Performance Obligation, Amount											$ 150,000
Medinet [Member] | Nonsoftware License Arrangement [Member]
Deferred Credits and Other Liabilities, Noncurrent								$ 1,000,000
Medinet [Member] | Below Market Rate Adjustment [Member]
Deferred Credits and Other Liabilities, Noncurrent								2,100,000
Lummy HK [Member]
Stock Issued During Period, Shares, New Issues				375,000
Proceeds from Milestone Payments				$ 1,050,000
Stock Purchase Agreement, Aggregate Purchase Price																$ 450,000	$ 1,500,000
Proceeds from Issuance of Common Stock				$ 450,000
Maximum [Member] | Pharmstandard [Member]
Royalties Percent of Net Sales																				20.00%
Maximum [Member] | Green Cross [Member]
Royalties Percent of Net Sales			20.00%
Maximum [Member] | Medinet [Member] | Developmental and Regulatory Milestones [Member]
Royalty Guarantees, Commitments, Amount								$ 9,000,000

Note 11 - Collaboration Agree50

Note 11 - Collaboration Agreements 2 (Details Textual) - Lummy License Agreement [Member]	Jun. 30, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-07-01
Revenue, Remaining Performance Obligation, Amount	$ 1,100,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Amount	1,200,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue, Remaining Performance Obligation, Amount	$ 2,300,000

Note 12 - Net Loss Per Share -

Note 12 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss	$ (6,478,715)	$ (8,538,611)	$ (8,589,984)	$ (32,618,690)
Weighted average common shares outstanding, basic and diluted (in shares)	10,584,644	2,068,743	9,109,917	2,067,218
Net loss per share, basic and diluted (in dollars per share)	$ (0.61)	$ (4.13)	$ (0.94)	$ (15.78)

Note 12 - Net Loss Per Share 52

Note 12 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Stock Option [Member]
Antidilutive Securities (in shares)	200,954	293,995	234,285	293,452
Warrant [Member]
Antidilutive Securities (in shares)	689,661	689,661	689,661	687,865
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	1,448,352		1,448,352